CD8A and COVID-19: The kinetics of immune changes in COVID-19 were investigated in serial blood samples from 207 SARS-CoV-2-infected individuals with a range of disease severities over 12 weeks from symptom onset.21 That study showed that mild/asymptomatic infection was associated with a robust adaptive immune cell response, with early rise and fall of effector CD8+ T cells and circulating plasmablasts, as well as transient complement activation, but no other evidence of systemic inflammation.